NVO Earnings & Financial Statements
Novo Nordisk A/S
$38.12
+$0.06(+0.16%)
47
Overall
85
Value
18
Tech
39
Quality
Market Cap
$168.79B
Volume
8.93M
52W Range
$35.12 - $64.16
Target Price
$46.38
NVO earnings and financial statements: Novo Nordisk A/S's income statement, balance sheet and cash flow statement, annual and quarterly.
NVO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $309.06B | $290.40B | $232.26B | $176.95B | $140.80B |
| Cost of revenue | $58.79B | $44.52B | $35.77B | $28.45B | $23.66B |
| Operating income | $127.66B | $128.34B | $102.57B | $73.78B | $58.64B |
| EBITDA | $159.30B | $153.64B | $114.93B | $77.89B | $65.39B |
| Net income | $102.43B | $100.99B | $83.68B | $54.01B | $47.76B |
| EPS (diluted) | - | $22.63 | $18.62 | $12.22 | $10.37 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $542.90B | $465.63B | $314.49B | $241.26B | $194.51B |
| Total liabilities | $348.86B | $322.14B | $207.93B | $278.71B | $123.76B |
| Shareholders’ equity | $194.05B | $143.49B | $106.56B | $83.49B | $70.75B |
| Cash and equivalents | $26.46B | $15.65B | $14.39B | $12.65B | $10.72B |
| Long-term debt | $118.94B | $89.67B | $20.53B | $24.32B | $12.96B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $119.10B | $120.97B | $108.91B | $78.89B | $55.00B |
| Capital expenditure | - | - | - | - | -$7.38B |
| Free cash flow | $28.99B | $69.66B | $70.01B | $64.13B | $40.51B |
| Dividends paid | $51.76B | $44.14B | $31.77B | $25.30B | $21.52B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVO | $38.12 | +0.2% | 8.93M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |